Plain-English translation of NCT03667170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called to treat advanced cancers — including colorectal and other solid tumors — that have specific genetic characteristics called mismatch repair deficiency or microsatellite instability. These genetic features may help the medication work better by boosting your immune system to fight the cancer. The medication is given as an injection under the skin every three weeks.
For people with advanced cancer that has already progressed despite standard treatments, options are very limited. Research has shown that cancers with these specific genetic features may respond well to immunotherapy drugs, and this trial is testing whether this medication can help patients whose cancer has not responded to or has progressed after earlier treatments.
You likely qualify if…
You likely don't qualify if…
If you are accepted into this trial, you will receive as an injection under your skin once every three weeks. You will need to attend regular clinic visits for treatment administration and monitoring, including blood tests and imaging scans to check how the cancer is responding. The trial is designed to enroll about 200 patients total, and your participation would continue as long as the treatment is beneficial and you are tolerating it well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
3D Medicines (Sichuan) Co., Ltd.
Enrollment target
~200 participants
Started
August 2018
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lin Shen, MD
Peking Universtiy Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.